Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.39 |
| ▸ | TLR2 | O60603 | 2/20 | 0.38 |
| ▸ | MDM4 | O15151 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | HTR7 | P34969 | 2/20 | 0.36 |
| ▸ | HTR6 | P50406 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30924966 | 0.88 | MDM2 (0.40) | KMT2AMDM2TLR2MDM4TP53 | |
| SCHEMBL20371136 | 0.87 | MDM2 (0.46) | KMT2AMDM2MDM4TP53 | |
| SCHEMBL574677 | 0.85 | KMT2A (0.55) | KMT2AMDM2TLR2MDM4TP53 | |
| SCHEMBL8843737 | 0.85 | KMT2A (0.52) | KMT2AMDM2TLR2MDM4TP53 | |
| SCHEMBL25631518 | 0.82 | KMT2A (0.45) | KMT2AMDM2TLR2MDM4TP53 | |
| SCHEMBL889833 | 0.82 | KMT2A (0.46) | KMT2AMDM2TLR2MDM4TP53 | |
| SCHEMBL3423921 | 0.82 | KMT2A (0.46) | KMT2AMDM2TLR2MDM4TP53 | |
| SCHEMBL18349843 | 0.81 | HDAC1 (0.45) | KMT2AHDAC6SMN1; SMN2 | |
| SCHEMBL8586600 | 0.81 | KMT2A (0.50) | KMT2AMDM2TLR2MDM4TP53 | |
| SCHEMBL13169256 | 0.81 | KMT2A (0.50) | KMT2AMDM2TLR2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491805-B2 | Biological conjugates used for drug delivery; side effect reduction | SIRNA THERAPEUTICS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20040249178-A1 | Biological conjugates used for drug delivery; side effect reduction | SIRNA THERAPEUTICS, INC. (US) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040249178-A1 | Biological conjugates used for drug delivery; side effect reduction | ALB, HEXA, ADAR | KMT2A 996/4885MDM2 1939/4885HDAC6 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.